Altimmune (ALT) grants CFO 259,000 options and 111,000 RSUs

Rhea-AI Filing Summary

WEAVER GREGORY L reported acquisition or exercise transactions in this Form 4 filing.

Altimmune, Inc. reported that its Chief Financial Officer, Gregory L. Weaver, was granted stock-based awards on February 26, 2026. He received stock options covering 259,000 shares of common stock and 111,000 Restricted Stock Units (RSUs), both held as direct ownership.

The option grant vests over four years, with 25% of the shares vesting on February 26, 2027 and the remaining shares vesting in equal monthly installments over the following 36 months, subject to his continued service. Each RSU represents a contingent right to receive one share of common stock and vests over four years, with 25% of the RSUs vesting on February 26, 2027 and the remainder in equal annual installments over the next three years, also subject to continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEAVER GREGORY L

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (option to buy)	$4.46	02/26/2026		A		259,000		(1)	02/26/2036	Common Stock, par value $0.0001	259,000	$0	259,000	D
Restricted Stock Units	(2)	02/26/2026		A		111,000		(3)	(3)	Common Stock, par value $0.0001	111,000	$0	111,000	D

Explanation of Responses:

1. The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on February 26, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

3. The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

	/s/ Gregory Weaver, as Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Altimmune (ALT) report for its CFO?

Altimmune reported that its Chief Financial Officer, Gregory L. Weaver, received equity awards on February 26, 2026, consisting of stock options for 259,000 shares and 111,000 Restricted Stock Units, all held as direct ownership according to the Form 4 filing.

How many stock options did Altimmune (ALT) grant to its CFO?

Altimmune granted its CFO stock options covering 259,000 shares of common stock. These options vest over four years, with 25% vesting on February 26, 2027 and the remaining portion vesting in equal monthly installments over the following 36 months, subject to continued service.

What are the terms of the Restricted Stock Units granted by Altimmune (ALT)?

Altimmune granted its CFO 111,000 Restricted Stock Units, each representing a contingent right to receive one share of common stock when vested. The RSUs vest over four years: 25% on February 26, 2027 and the rest in equal annual installments over the next three years, subject to continued service.

When do the Altimmune (ALT) CFO’s stock options begin vesting?

The CFO’s stock options begin vesting on February 26, 2027, when 25% of the 259,000 option shares vest. The remaining shares then vest in equal monthly installments over the following 36 months, contingent on his continued service with the company throughout the vesting period.

How long is the vesting period for Altimmune (ALT) CFO’s RSUs?

The Restricted Stock Units granted to Altimmune’s CFO vest over four years. Twenty-five percent of the 111,000 RSUs vest on February 26, 2027, with the remaining RSUs vesting in equal annual installments over the subsequent three years, assuming continued service on each vesting date.

What does each Altimmune (ALT) Restricted Stock Unit represent in this Form 4?

Each Restricted Stock Unit reported for Altimmune’s CFO represents a contingent right to receive one share of common stock, par value $0.0001, upon vesting. The RSUs have no expiration date and are subject to the specified four-year vesting schedule linked to continued service.